**Abbreviations**



**References**

[1] Dexter DT, Jenner P. Parkinson disease: From pathology to molecular disease mechanisms.

Animal Model of Parkinson Disease: Neuroinflammation and Apoptosis in the…

http://dx.doi.org/10.5772/intechopen.71271

385

[2] Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson's disease.

[3] Double KL. Neuronal vulnerability in Parkinson's disease. Parkinsonism & Related

[4] Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, et al. Parkindeficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. The

[5] Shaltouki A, Sivapatham R, Pei Y, Gerencser AA, Momcilovic O, Rao MS, etal. Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines. Stem Cell Reports. 2015;**4**(5):847-859 Epub 07-04-2015

[6] Blesa J, Przedborski S. Parkinson's disease: Animal models and dopaminergic cell vul-

[7] Bendor JT, Logan TP, Edwards RH. The function of alpha-synuclein. Neuron. 2013;

[8] Lindgren HS, Lelos MJ, Dunnett SB. Do alpha-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model? Experimental

[9] Huang D, Xu J, Wang J, Tong J, Bai X, Li H, et al. Dynamic changes in the nigrostriatal pathway in the MPTP mouse model of Parkinson's disease. Parkinson's Disease.

[10] Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neu-

[11] Nistico R, Mehdawy B, Piccirilli S, Mercuri N. Paraquat- and rotenone-induced models of Parkinson's disease. International Journal of Immunopathology and Pharmacology.

[12] Tieu K. A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harbor

[13] Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apop-

[14] Altar CA, Heikkila RE, Manzino L, Marien MR. 1-Methyl-4-phenylpyridine (MPP+): Regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation. European Journal of Pharmacology. 1986;**131**(2-3):199-209

totic theory in Parkinson's disease. Progress in Neurobiology. 2001;**65**(2):135-172

Journal of Biological Chemistry. 2003;**278**(44):43628-43635 Epub 22-08-2003

Free Radical Biology & Medicine. 2013;**62**:132-144

nerability. Frontiers in Neuroanatomy. 2014;**8**:155

rons. European Journal of Pharmacology. 1968;**5**(1):107-110

Movement Disorders. 2013;**28**(1):41-50

Disorders. 2012;**18**(Suppl 1):S52-S54

**79**(6):1044-1066

Neurology. 2012;**237**(1):36-42

2017;**2017**:9349487 Epub 24-08-2017

2011;**24**(2):313-322 Epub 11-06-2011

Perspectives in Medicine. 2011;**1**(1):a009316
